William Blair Issues Negative Forecast for OCUL Earnings

Ocular Therapeutix, Inc. (NASDAQ:OCUL) – Research analysts at William Blair decreased their Q2 2025 earnings estimates for Ocular Therapeutix in a note issued to investors on Monday, May 5th. William Blair analyst L. Hanbury-Brown now forecasts that the biopharmaceutical company will post earnings of ($0.35) per share for the quarter, down from their prior estimate of ($0.30). William Blair has a “Outperform” rating on the stock. The consensus estimate for Ocular Therapeutix’s current full-year earnings is ($0.98) per share. William Blair also issued estimates for Ocular Therapeutix’s Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.44) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.33) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.35) EPS and FY2026 earnings at ($1.36) EPS.

Several other equities research analysts also recently weighed in on OCUL. Royal Bank of Canada initiated coverage on Ocular Therapeutix in a report on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 price target for the company. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a research note on Tuesday, March 4th. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Finally, Needham & Company LLC lowered their price target on Ocular Therapeutix from $15.00 to $14.00 and set a “buy” rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Ocular Therapeutix currently has an average rating of “Moderate Buy” and an average price target of $16.25.

Ocular Therapeutix Stock Performance

Shares of OCUL opened at $7.11 on Thursday. Ocular Therapeutix has a 12 month low of $4.79 and a 12 month high of $11.78. The stock has a fifty day moving average price of $7.46 and a 200-day moving average price of $8.29. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The firm has a market cap of $1.13 billion, a PE ratio of -5.39 and a beta of 1.51.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The firm had revenue of $17.08 million for the quarter, compared to analysts’ expectations of $16.89 million.

Insider Activity

In related news, insider Pravin Dugel sold 21,475 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the sale, the insider now directly owns 3,520,318 shares of the company’s stock, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. GF Fund Management CO. LTD. acquired a new position in Ocular Therapeutix in the 4th quarter worth about $28,000. Atlas Capital Advisors Inc. acquired a new position in shares of Ocular Therapeutix during the 4th quarter worth approximately $43,000. AlphaQuest LLC purchased a new position in shares of Ocular Therapeutix during the 4th quarter valued at approximately $53,000. GAMMA Investing LLC grew its stake in Ocular Therapeutix by 6,760.0% in the 1st quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 8,112 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in Ocular Therapeutix by 2,045.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,859 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 8,446 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.